Honest Company Inc vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Honest Company Inc trades at $5.04 (market cap $533.20M), while Royalty Pharma plc Class A Ordinary Shares trades at $56.96 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 47.4× Honest Company Inc's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Honest Company Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Honest Company Inc for 39 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| HNST | RPRX | |
|---|---|---|
Market Cap | $533.20M | $25.27B |
Volume | 1,990,155 | 3,671,183 |
Sector | Consumer Staples | Health |
52-Week High | $5.95 | $63.96 |
52-Week Low | $2.10 | $35.44 |
Typical Hold Time | 39 Days | 1 Days |
Enterprise Value | $436.81M | $32.50B |
Dividend Yield | — | 1.66% |
Signals from Pluang's Aura AI — not financial advice
HNST trades at $4.99, up 1.22% today, with a bearish technical signal despite recent positive earnings momentum. The company shows mixed fundamentals with revenue of $371.32M in 2025 but negative net income margins. Recent Q2 2026 earnings beat expectations with $0.04 EPS, and institutional interest is growing with BlackRock's $25.66M investment in August 2026.
The stock faces headwinds from persistent unprofitability and declining revenue projections for 2026, though strategic exits are improving margins. Analyst consensus is mixed with a $5.30 price target, suggesting limited upside. Key risks include execution on profitability and competitive pressures in personal care markets.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →